Genolution Inc. Cash Flow Conversion Efficiency
Genolution Inc. cash flow conversion efficiency. Based on the latest financial reports, Genolution Inc. (225220) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-927.21 Million ≈ $-628.35K USD) by net assets (₩73.39 Billion ≈ $49.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Genolution Inc. (2016–2024)
Cash flow conversion efficiency of Genolution Inc. from 2016 to 2024. This chart illustrates how Genolution Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Genolution Inc. (225220) share price today for real-time trading data and today's change.
Genolution Inc. Cash Flow Conversion Ratio Explained
Genolution Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Genolution Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genolution Inc. ranked by their cash flow conversion efficiency. Also see 225220 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lung Hwa Electronics Co Ltd
TW:2424
|
-0.057x |
|
Aarvi Encon Limited
NSE:AARVI
|
0.045x |
|
NanoViricides Inc
NYSE MKT:NNVC
|
-0.222x |
|
Beeline Holdings, Inc.
NASDAQ:BLNE
|
-0.071x |
|
Hermana Holding ASA
OL:HERMA
|
-0.040x |
|
Desoto Resources Ltd
AU:DES
|
-0.226x |
|
G11 Resources Ltd
AU:G11
|
-0.022x |
|
Anugerah Kagum Karya Utama Tbk PT
JK:AKKU
|
0.000x |
Annual Cash Flow Conversion Efficiency for Genolution Inc. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Genolution Inc. from 2016 to 2024. Review free cash flow generation of Genolution Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩80.29 Billion ≈ $54.41 Million |
₩-1.43 Billion ≈ $-970.93K |
-0.018x | -37.43% |
| 2023-12-31 | ₩87.45 Billion ≈ $59.26 Million |
₩-1.14 Billion ≈ $-769.54K |
-0.013x | -109.07% |
| 2022-12-31 | ₩94.70 Billion ≈ $64.18 Million |
₩13.55 Billion ≈ $9.18 Million |
0.143x | -54.29% |
| 2021-12-31 | ₩82.20 Billion ≈ $55.71 Million |
₩25.73 Billion ≈ $17.44 Million |
0.313x | -58.26% |
| 2020-12-31 | ₩61.29 Billion ≈ $41.54 Million |
₩45.97 Billion ≈ $31.15 Million |
0.750x | +2556.06% |
| 2019-12-31 | ₩2.64 Billion ≈ $1.79 Million |
₩-80.58 Million ≈ $-54.61K |
-0.031x | -160.85% |
| 2018-12-31 | ₩2.94 Billion ≈ $1.99 Million |
₩147.49 Million ≈ $99.95K |
0.050x | -72.00% |
| 2017-12-31 | ₩4.00 Billion ≈ $2.71 Million |
₩717.13 Million ≈ $485.99K |
0.179x | +2372.91% |
| 2016-12-31 | ₩3.42 Billion ≈ $2.32 Million |
₩-27.00 Million ≈ $-18.30K |
-0.008x | -- |
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more